Genenta Science S.p.A. (GNTA)
Uses modified immune cells to attack solid tumors like brain cancer.
$1.57-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-58.9%
The outlook
GNTA is trading near its 52-week lows, well below both its 50- and 200-day moving averages despite sitting technically above them. Analyst coverage appears limited, and the overall StockGlow score sits at neutral. The stock remains in the lower portion of its annual range.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Market cap
$75.7M
52-wk high
$10.00
52-wk low
$0.55
50-day avg
$1.49
200-day avg
$1.46
Trailing P/E
—